xentuzumab
mAbexperimental
Clinical trial activity
3 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started May 4, 2017 (NCT03099174)
Timeline
Indications
Mechanism of action
- Insulin-like growth factor IIINHIBITOR
Insulin-like growth factor II inhibitor
- Insulin-like growth factor IINHIBITOR
Insulin-like growth factor I inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4297850 ↗
Also known as
- xentuzumab
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05110495 | Early Phase 1 (Phase 1) | Dec 31, 2021 | Boehringer Ingelheim, Prostate Cancer UK, University of Oxford |
| NCT03659136 | Phase 2 | Nov 19, 2018 | Boehringer Ingelheim |
| NCT03099174 | Phase 1 | May 4, 2017 | Boehringer Ingelheim |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Boehringer Ingelheim | For profit | 3 | 2 | 2 | 2017 |
| Prostate Cancer UK | Academic/Hospital | 1 | 0 | 1 | 2021 |
| University of Oxford | Academic/Hospital | 1 | 1 | 1 | 2021 |
3 organizations
Page 1 / 1